Search Results - "Baz, D. Vicente"

974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC) by Novello, S., Kowalski, D.M., Luft, A., Gumus, M., Vicente Baz, D., Mazieres, J., Rodriguez Cid, J.R., Tafreshi, A., Cheng, Y., Lee, K.H., Golf, A., Sugawara, S., Robinson, A.G., Halmos, B., Jensen, E., Schwarzenberger, P.O., Pietanza, M.C., Paz-Ares, L.

Get full text

509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 by Ahn, M-J., Lisberg, A.E., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo Dols, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Sands, J., Hall, R., Zhang, Y., Zebger-Gong, H., Uema, D., Okamoto, I.

Get full text

LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 by Ahn, M-J., Lisberg, A., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo Dols, M., Pérol, M., Mascaux, C., Poddubskaya, E., Kitazono, S., Hayashi, H., Sands, J., Hall, R., Zhang, Y., Zebger-Gong, H., Uema, D., Okamoto, I.

Get full text

1384P Prognostic factors for survival in patients with metastatic lung adenocarcinoma: Analysis of the SEER database by Balea, B. Campos, de Castro Carpeño, J., Massuti, B., Vicente-Baz, D., Parente, D. Pérez, Gracia, P. Ruiz, Dols, M. Cobo

Get full text

Multicenter study of weekly trastuzumab, paclitaxel and carboplatin followed by a week of rest every 28 days in patients with HER2+ metastatic breast cancer – incidence of central nervous system metastases by Salvador, J, Ruiz-Borrego, M, Bayo-Calero, J, Lomas-Garrido, M, Moreno-Vega, A, Bernabé, R, Valero, M, Vicente-Baz, D, Fuentes, J, López-Ladrón, A

Get full text

LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen by Lee, S.M., Schulz, C., Prabhash, K., Han, B., Szczesna, A., Cortinovis, D.L., Rittmeyer, A., Baz, D. Vicente, Califano, R., Anh, L. Tuan, Liu, G., Cappuzzo, F., Contreras, J.G. Reyes, Reck, M., Hu, Y., Morris, S., Hoeglander, E.K., Connors, M., Vollan, H.K.M., Peters, S.

Get full text

60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study by Cappuzzo, F., Patel, J., Cho, B.C., Dols, M. Cobo, Cabanillas, R.M. Reyes, Baz, D. Vicente, Pradera, J. Fuentes, Neal, J., Garon, E.B., Mekan, S., Safavi, F., Fernando, N., Chisamore, M., Reck, M.

Get full text

59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial by Girard, N., Okamoto, I., Lisberg, A.E., Pons-Tostivint, E., Cornelissen, R., Hong, M.H., Paz-Ares, L., Baz, D. Vicente, Sugawara, S., Dols, M. Cobo, Pérol, M., Mascaux, C., Felip, E., Le Guen, Y., Sands, J., Chargualaf, M., Zhang, Y., Howarth, P., Uema, D., Ahn, M-J.

Get full text

Preliminar analysis of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): NORA trial (GECP 15/02) by Majem Tarruella, M., Isla Casado, L., Guirado, M., Massuti Sureda, B., Ortega Granados, A.L., Marse Fabregat, R., Domine Gomez, M., de las Peñas, R., Moran Bueno, M.T., Vazquez Estevez, S., Sala Gonzalez, M.A., Coves Sarto, J., Sánchez-Torres, J.M., Vicente Baz, D., Gonzalez-Larriba, J., Paredes, A., Farré, N., Fernández Fornos, L., Mena, A., Provencio Pulla, M.

Get full text

Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study” NADIM trial by Calvo de Juan, V., Insa Molla, A., Cobo Dols, M., Massuti Sureda, B., Lopez-Vivanco, G., Casal Rubio, J., de Castro, J., Majem Tarruella, M., Bernabe Caro, R., Gonzalez-Larriba, J., Barneto Aranda, I.C., Nadal, E., Martinez Marti, A., Vinolas Segarra, N., Guillot Morales, M., Vicente Baz, D., Camps Herrero, C., Domine Gomez, M., Rodriguez Abreu, D., Provencio Pulla, M.

Get full text

Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): A case-control study from GEIS by Serrano, C., Lopez Pousa, A., Pajares, I., Valverde Morales, C., Duran, J., Rubió-Casadevall, J., Safont, M.J., Martinez, V., Díaz Beveridge, R., Estival, A., Vicente Baz, D., Sebio Garcia, A., Hindi, N., Landolfi, S., Olivares, D., Garcia-Valverde, A., Ledesma, P., Arribas, J., Carles Galceran, J., Martin Broto, J.

Get full text

A propósito de un caso: linfoma mediastínico y cirugía by Vicente Baz, D., Calvo García, E., Moreno Nogueira, J. A.

“…PROPÓSITO: el linfoma B primario mediastínico (LBPM) es una entidad clínico-patológica diferenciada reconocida en la clasificación REAL¹. Constituye una…”
Get full text

Infección VIH y sarcoma de Kaposi: a propósito de un caso by Vicente Baz, D., Fernández Delgado, C.

Get full text

Infección por el virus de la inmunodeficiencia humana y seminoma by Vicente Baz, D., Rodríguez Jiménez, A., Fernández-Freire-Leal, A., Montaño Periañez, A.

Get full text

A propósito de un caso: linfoma mediastínico y cirugía by Vicente Baz, D., Calvo García, E., Moreno Nogueira, J. A.

Get full text

Dermatomiositis y adenocarcinoma pancreático: Resolución tras gemcitabina by Vicente Baz, D., Fernández Delgado, C., Toda Savall, R., Masabeu Urrutia, A.

Get full text

Infección VIH y sarcoma de Kaposi: a propósito de un caso by Vicente Baz, D., Fernández Delgado, C.

“…PROPÓSITO: El sarcoma de Kaposi es el cáncer más frecuente entre los pacientes con infección VIH aunque el riesgo ha disminuido con el tratamiento…”
Get full text

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC by Andric, Zoran, Gálffy, Gabriella, Cobo Dols, Manuel, Szima, Barna, Stojanovic, Goran, Petrovic, Marina, Felip, Enriqueta, Vicente Baz, David, Ponce Aix, Santiago, Juan-Vidal, Oscar, Szalai, Zsuzsanna, Losonczy, Gyorgy, Calles Blanco, Antonio, Bernabe, Reyes, García Ledo, Gema, Aguilar Hernández, Andrés, Duecker, Klaus, Zhou, Dongli, Schroeder, Andreas, Guezel, Guelseren, Ciardiello, Fortunato

“…We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients…”
Get full text

Enfermedad de Hodgkin epitroclear: Aportación de un nuevo caso by Vicente Baz, D., Ruiz Borrego, M., Arriola Arellano, E., Fernández-Freire, A., Moreno Nogueira, J. A.

Get full text

Infección por el virus de la inmunodeficiencia humana y seminoma by Vicente Baz, D., Rodríguez Jiménez, A., Fernández-Freire-Leal, A., Montaño Periañez, A.

“…PROPÓSITO: Los tumores germinales son más frecuentes en pacientes con infección VIH que en la población general. Realizamos una revisión bibliográfica de esta…”
Get full text